Advances in functional lipid nanoparticles: from drug delivery platforms to clinical applications
Abstract Since Doxil's first clinical approval in 1995, lipid nanoparticles have garnered great interest and shown exceptional therapeutic efficacy. It is clear from the licensure of two RNA treatments and the mRNA-COVID-19 vaccination that lipid nanoparticles have immense potential for delivering nucleic acids. The review begins with a list of lipid nanoparticle types, such as liposomes and solid lipid nanoparticles. Then it moves on to the earliest lipid nanoparticle forms, outlining how lipid is used in a variety of industries and how it is used as a versatile nanocarrier platform. Lipid nanoparticles must then be functionally modified. Various approaches have been proposed for the synthesis of lipid nanoparticles, such as High-Pressure Homogenization (HPH), microemulsion methods, solvent-based emulsification techniques, solvent injection, phase reversal, and membrane contractors. High-pressure homogenization is the most commonly used method. All of the methods listed above follow four basic steps, as depicted in the flowchart below. Out of these four steps, the process of dispersing lipids in an aqueous medium to produce liposomes is the most unpredictable step. A short outline of the characterization of lipid nanoparticles follows discussions of applications for the trapping and transporting of various small molecules. It highlights the use of rapamycin-coated lipid nanoparticles in glioblastoma and how lipid nanoparticles function as a conjugator in the delivery of anticancer-targeting nucleic acids. High biocompatibility, ease of production, scalability, non-toxicity, and tailored distribution are just a meager of the enticing allowances of using lipid nanoparticles as drug delivery vehicles. Due to the present constraints in drug delivery, more research is required to utterly realize the potential of lipid nanoparticles for possible clinical and therapeutic purposes..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
3 Biotech - 14(2024), 2 vom: 29. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dhayalan, Manikandan [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Biocompatibility |
|---|
| Anmerkungen: |
© King Abdulaziz City for Science and Technology 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s13205-023-03901-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054568366 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054568366 | ||
| 003 | DE-627 | ||
| 005 | 20240209064658.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240130s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13205-023-03901-8 |2 doi | |
| 035 | |a (DE-627)SPR054568366 | ||
| 035 | |a (SPR)s13205-023-03901-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dhayalan, Manikandan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Advances in functional lipid nanoparticles: from drug delivery platforms to clinical applications |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © King Abdulaziz City for Science and Technology 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract Since Doxil's first clinical approval in 1995, lipid nanoparticles have garnered great interest and shown exceptional therapeutic efficacy. It is clear from the licensure of two RNA treatments and the mRNA-COVID-19 vaccination that lipid nanoparticles have immense potential for delivering nucleic acids. The review begins with a list of lipid nanoparticle types, such as liposomes and solid lipid nanoparticles. Then it moves on to the earliest lipid nanoparticle forms, outlining how lipid is used in a variety of industries and how it is used as a versatile nanocarrier platform. Lipid nanoparticles must then be functionally modified. Various approaches have been proposed for the synthesis of lipid nanoparticles, such as High-Pressure Homogenization (HPH), microemulsion methods, solvent-based emulsification techniques, solvent injection, phase reversal, and membrane contractors. High-pressure homogenization is the most commonly used method. All of the methods listed above follow four basic steps, as depicted in the flowchart below. Out of these four steps, the process of dispersing lipids in an aqueous medium to produce liposomes is the most unpredictable step. A short outline of the characterization of lipid nanoparticles follows discussions of applications for the trapping and transporting of various small molecules. It highlights the use of rapamycin-coated lipid nanoparticles in glioblastoma and how lipid nanoparticles function as a conjugator in the delivery of anticancer-targeting nucleic acids. High biocompatibility, ease of production, scalability, non-toxicity, and tailored distribution are just a meager of the enticing allowances of using lipid nanoparticles as drug delivery vehicles. Due to the present constraints in drug delivery, more research is required to utterly realize the potential of lipid nanoparticles for possible clinical and therapeutic purposes. | ||
| 650 | 4 | |a Rapamycin-coated lipid |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Lipid nanoparticles |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nucleic acid medications |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Biocompatibility |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nontoxicity |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Targeted delivery |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Wang, Wei |4 aut | |
| 700 | 1 | |a Riyaz, S. U. Mohammed |4 aut | |
| 700 | 1 | |a Dinesh, Rakshi Anuja |4 aut | |
| 700 | 1 | |a Shanmugam, Jayashree |4 aut | |
| 700 | 1 | |a Irudayaraj, Santiagu Stephen |4 aut | |
| 700 | 1 | |a Stalin, Antony |4 aut | |
| 700 | 1 | |a Giri, Jayant |4 aut | |
| 700 | 1 | |a Mallik, Saurav |0 (orcid)0000-0003-4107-6784 |4 aut | |
| 700 | 1 | |a Hu, Ruifeng |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t 3 Biotech |d Berlin : Springer, 2011 |g 14(2024), 2 vom: 29. Jan. |w (DE-627)SPR030851394 |w (DE-600)2600522-0 |x 2190-5738 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:2 |g day:29 |g month:01 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13205-023-03901-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 2 |b 29 |c 01 | ||